<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="2.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Med.</journal-id>
<journal-title>Frontiers in Medicine</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Med.</abbrev-journal-title>
<issn pub-type="epub">2296-858X</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fmed.2025.1601863</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Medicine</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Association between overactive bladder and lipid accumulation product and visceral adiposity index: results from NHANES 2005&#x2013;2018</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Wang</surname> <given-names>Wenhao</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/3013330/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/supervision/"/>
<role content-type="https://credit.niso.org/contributor-roles/visualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/software/"/>
<role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/validation/"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
<role content-type="https://credit.niso.org/contributor-roles/resources/"/>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/project-administration/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Tao</surname> <given-names>Anran</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Xing</surname> <given-names>Ziyi</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Xu</surname> <given-names>Xiaolin</given-names></name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<xref ref-type="corresp" rid="c001"><sup>&#x002A;</sup></xref>
<role content-type="https://credit.niso.org/contributor-roles/supervision/"/>
<role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
<role content-type="https://credit.niso.org/contributor-roles/visualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/resources/"/>
</contrib>
</contrib-group>
<aff id="aff1"><sup>1</sup><institution>The First Affiliated Hospital of Anhui University of Science and Technology, Huainan</institution>, <addr-line>Anhui</addr-line>, <country>China</country></aff>
<aff id="aff2"><sup>2</sup><institution>Shanghai Fengxian District Central Hospital</institution>, <addr-line>Shanghai</addr-line>, <country>China</country></aff>
<author-notes>
<fn fn-type="edited-by" id="fn0001">
<p>Edited by: Arch Mainous, University of Florida, United States</p>
</fn>
<fn fn-type="edited-by" id="fn0002">
<p>Reviewed by: Vikrant Rai, Western University of Health Sciences, United States</p>
<p>Farhad Tondroanamag, Tabriz University of Medical Sciences, Iran</p>
<p>Maria Dyah Kurniasari, Satya Wacana Christian University, Indonesia</p>
</fn>
<corresp id="c001">&#x002A;Correspondence: Xiaolin Xu, <email>xnw7789@alumni.sjtu.edu.cn</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>14</day>
<month>07</month>
<year>2025</year>
</pub-date>
<pub-date pub-type="collection">
<year>2025</year>
</pub-date>
<volume>12</volume>
<elocation-id>1601863</elocation-id>
<history>
<date date-type="received">
<day>28</day>
<month>03</month>
<year>2025</year>
</date>
<date date-type="accepted">
<day>25</day>
<month>06</month>
<year>2025</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#x00A9; 2025 Wang, Tao, Xing and Xu.</copyright-statement>
<copyright-year>2025</copyright-year>
<copyright-holder>Wang, Tao, Xing and Xu</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<sec id="sec1">
<title>Background</title>
<p>Although obesity is a recognized risk factor contributing to the onset and progression of overactive bladder (OAB), the existing evidence linking lipid accumulation products (LAPs) and the visceral adiposity index (VAI) to OAB remains scarce and subject to debate. Hence, this study was conducted to evaluate the associations between VAI, LAP, and the occurrence of OAB.</p>
</sec>
<sec id="sec2">
<title>Methods</title>
<p>The information utilized in this research was sourced from the National Health and Nutrition Examination Survey (NHANES), spanning the years 2005 to 2018. The majority of the data pertaining to OAB relied on self-administered questionnaires. To assess the relationships between VAI, LAP, and OAB, we employed multivariate logistic regression models, trend analysis, and subgroup evaluations.</p>
</sec>
<sec id="sec3">
<title>Results</title>
<p>The study encompassed a total of 70,190 participants, with 22,928 individuals diagnosed with OAB and 5,776 serving as controls. After accounting for potential confounding factors, a statistically significant positive relationship was noted between both the visceral adiposity index (VAI) and the lipid accumulation product (LAP), as well as the occurrence of overactive bladder (OAB). Respectively, individuals in the highest quartiles of LAP and VAI demonstrated a 56% (OR&#x202F;=&#x202F;1.555, 95% CI: 1.376&#x2013;1.758) and 22% (OR&#x202F;=&#x202F;1.225, 95% CI: 1.084&#x2013;1.384) increased probability of OAB when compared to those in the lowest quartile. Additional subgroup analyses revealed that the observed associations were particularly evident in participants under the age of 60 and among women.</p>
</sec>
<sec id="sec4">
<title>Conclusion</title>
<p>This study&#x2019;s findings suggest that an increase in both the visceral adiposity index (VAI) and lipid accumulation product (LAP) is associated with a greater occurrence of overactive bladder (OAB), hinting at their possible use as predictive indicators for OAB.</p>
</sec>
</abstract>
<kwd-group>
<kwd>overactive bladder (OAB)</kwd>
<kwd>lipid accumulation product (LAP)</kwd>
<kwd>visceral adiposity index (VAI)</kwd>
<kwd>NHANES (National Health and Nutrition Examination Survey)</kwd>
<kwd>obesity</kwd>
</kwd-group>
<contract-num rid="cn1">201840245</contract-num>
<contract-sponsor id="cn1">Fengxian District Central Hospital of Shanghai</contract-sponsor>
<counts>
<fig-count count="2"/>
<table-count count="4"/>
<equation-count count="4"/>
<ref-count count="41"/>
<page-count count="9"/>
<word-count count="6054"/>
</counts>
<custom-meta-wrap>
<custom-meta>
<meta-name>section-at-acceptance</meta-name>
<meta-value>Family Medicine and Primary Care</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<sec sec-type="intro" id="sec5">
<title>Introduction</title>
<p>Overactive bladder (OAB), as defined by International Continence Society (ICS) guidelines, is a clinical syndrome characterized primarily by urinary urgency. It occurs in the absence of urinary tract infections or other identifiable pathological conditions. The syndrome is frequently associated with increased frequency and nocturia, with or without urgency urinary incontinence (<xref ref-type="bibr" rid="ref1">1</xref>, <xref ref-type="bibr" rid="ref2">2</xref>). According to epidemiological research, the incidence of OAB stands at 10.8% among males and 12.8% among females (<xref ref-type="bibr" rid="ref3">3</xref>). Furthermore, the incidence of OAB escalates with advancing age. As the global population expands and ages, the socioeconomic impact of OAB is progressively intensifying (<xref ref-type="bibr" rid="ref4">4</xref>). However, the underlying pathophysiological mechanisms of OAB are still not fully elucidated, current research indicates that a multitude of factors, such as neuromodulation of the bladder, muscular tissue involvement, central nervous system regulation, inflammatory processes, and metabolic disturbances, may collectively play a role in the development of this condition (<xref ref-type="bibr" rid="ref5">5</xref>). Consequently, the identification of novel biomarkers with a well-established association to the pathogenesis of overactive bladder (OAB) holds significant potential for advancing the understanding of disease mechanisms and facilitating targeted exploration of therapeutic intervention targets.</p>
<p>Numerous studies have emphasized the crucial part obesity plays in the onset and advancement of OAB (<xref ref-type="bibr" rid="ref6">6</xref>). A key characteristic of obesity is the accumulation of visceral adipose tissue. Nonetheless, conventional metrics like body mass index (BMI) and waist circumference (WC) offer only a rough estimation of obesity, without incorporating metabolic indicators, and lack the capacity to differentiate between subcutaneous and visceral fat deposits (<xref ref-type="bibr" rid="ref7">7</xref>). The lipid accumulation product (LAP) incorporates measures of waist circumference and triglyceride levels, serving as an indicator of adipose tissue accumulation and metabolic impairment (<xref ref-type="bibr" rid="ref8">8</xref>). Waist circumference, BMI, high-density lipoprotein (HDL) cholesterol levels, and triglyceride concentrations are all taken into consideration by the visceral adiposity index (VAI), which evaluates the distribution and functioning of visceral fat (<xref ref-type="bibr" rid="ref9">9</xref>). Compared with traditional anthropometric indicators (e.g., BMI, WC), these indices demonstrate superior predictive performance for the risk of metabolic syndrome and cardiovascular diseases, as well as enhanced utility in mechanistic research on chronic inflammation and insulin resistance. These two indices act as reliable markers of visceral fat buildup and metabolic disorders. They quantify obesity and hint at visceral fat&#x2019;s impact on bladder function (<xref ref-type="bibr" rid="ref10">10</xref>, <xref ref-type="bibr" rid="ref11">11</xref>). In specific clinical scenarios, their predictive capability may even exceed that of traditional measurements like BMI (<xref ref-type="bibr" rid="ref12">12</xref>). Previous studies have also established associations between LAP, VAI, and other diseases (<xref ref-type="bibr" rid="ref13">13</xref>, <xref ref-type="bibr" rid="ref14">14</xref>). To date, the relationship between overactive bladder (OAB) and lipid accumulation product (LAP)/visceral adiposity index (VAI) has not been investigated in any published studies.</p>
<p>The foundation of this study is the National Health and Nutrition Examination Survey (NHANES) database, a comprehensive clinical dataset meticulously maintained by the National Center for Health Statistics (NCHS). Leveraging data from the NHANES database encompassing the years 2005 to 2018, this research endeavors to evaluate the potential association between LAP, VAI, and OAB, ultimately aiming to provide multi-dimensional evidence support for the health management of OAB.</p>
</sec>
<sec sec-type="methods" id="sec6">
<title>Methods</title>
<sec id="sec7">
<title>Study population</title>
<p>The data for this analysis originated from the National Health and Nutrition Examination Survey (NHANES), conducted between 2005 and 2018. NHANES is a research endeavor administered by the Centers for Disease Control and Prevention (CDC), intended to gather exhaustive information on the health status, dietary habits, and lifestyles of the U.S. populace. It employs a sophisticated, multi-stage stratified sampling technique to collect these data. The protocols employed in NHANES were cleared by the Review Board of the National Center for Health Statistics (NCHS). All participants provided their informed consent. The NHANES database encompasses five key components: demographic information, screening results, dietary records, laboratory test outcomes, and questionnaire responses (<xref ref-type="bibr" rid="ref15">15</xref>). Additional information on the NHANES database is accessible at: <ext-link xlink:href="http://www.cdc.gov/nhanes" ext-link-type="uri">http://www.cdc.gov/nhanes</ext-link>.</p>
<p>In total, 70,190 participants were incorporated into the NHANES dataset spanning from 2005 to 2018. <xref ref-type="fig" rid="fig1">Figure 1</xref> depicts the exclusion criteria, which include: (1) participants with absent OAB data; (2) those lacking information on VAI and LAP; and (3) individuals missing covariate data or below the age of 20. Consequently, a final count of 28,704 samples was retained for the definitive analysis. The procedure for data selection is illustrated in <xref ref-type="fig" rid="fig1">Figure 1</xref>.</p>
<fig position="float" id="fig1">
<label>Figure 1</label>
<caption>
<p>Flow chart of patient screening.</p>
</caption>
<graphic xlink:href="fmed-12-1601863-g001.tif" mimetype="image" mime-subtype="tiff">
<alt-text content-type="machine-generated">Flowchart illustrating exclusion criteria for NHANES 2015-2018 participants. Starting with 70,190 participants, 35,706 were excluded due to incomplete urge urinary incontinence and nocturia data. Next, 2,857 were excluded for incomplete LAP and VAI data, reducing to 31,627. Finally, 2,923 were excluded due to unavailable covariate data and age under 20, ending with 28,704 participants.</alt-text>
</graphic>
</fig>
</sec>
<sec id="sec8">
<title>Definition of exposure variables</title>
<p>In this study, VAI and LAP were designated as the exposure variables. NHANES involved the measurement of triglyceride (TG) and high-density lipoprotein cholesterol (HDL-C) levels using fasting blood samples, which were collected by healthcare professionals at the Mobile Examination Centers (MECs). At the Mobile Examination Centers (MECs), waist circumference (WC) was assessed by skilled technicians using a tape measure, positioned at the midpoint of the axillary line just above the iliac crest during the end of a normal exhalation, with a precision of 0.1&#x202F;cm. The calculations for LAP and VAI were gender-specific and based on the following formulas, where TG and HDL were measured in mmol/L, WC in centimeters, and BMI in kilograms per square meter (<xref ref-type="bibr" rid="ref16">16</xref>).</p>
<disp-formula id="E1">
<mml:math id="M1">
<mml:mtext>Males</mml:mtext>
<mml:mo>:</mml:mo>
<mml:mi>LAP</mml:mi>
<mml:mo>=</mml:mo>
<mml:mo stretchy="true">(</mml:mo>
<mml:mi>WC</mml:mi>
<mml:mo>&#x2212;</mml:mo>
<mml:mn>65</mml:mn>
<mml:mo stretchy="true">)</mml:mo>
<mml:mo>&#x2217;</mml:mo>
<mml:mi>TG</mml:mi>
</mml:math>
</disp-formula>
<disp-formula id="E2">
<mml:math id="M2">
<mml:mtext>Females</mml:mtext>
<mml:mo>:</mml:mo>
<mml:mi>LAP</mml:mi>
<mml:mo>=</mml:mo>
<mml:mo stretchy="true">(</mml:mo>
<mml:mi>WC</mml:mi>
<mml:mo>&#x2212;</mml:mo>
<mml:mn>58</mml:mn>
<mml:mo stretchy="true">)</mml:mo>
<mml:mo>&#x2217;</mml:mo>
<mml:mi>TG</mml:mi>
</mml:math>
</disp-formula>
<disp-formula id="E3">
<mml:math id="M3">
<mml:mtext>Males</mml:mtext>
<mml:mo>:</mml:mo>
<mml:mi>VAI</mml:mi>
<mml:mo>=</mml:mo>
<mml:mo stretchy="true">(</mml:mo>
<mml:mfrac>
<mml:mi>WC</mml:mi>
<mml:mrow>
<mml:mn>39.68</mml:mn>
<mml:mo>+</mml:mo>
<mml:mn>1.88</mml:mn>
<mml:mo>&#x2217;</mml:mo>
<mml:mi>BMI</mml:mi>
</mml:mrow>
</mml:mfrac>
<mml:mo stretchy="true">)</mml:mo>
<mml:mo>&#x2217;</mml:mo>
<mml:mo stretchy="true">(</mml:mo>
<mml:mfrac>
<mml:mi>TG</mml:mi>
<mml:mn>1.03</mml:mn>
</mml:mfrac>
<mml:mo stretchy="true">)</mml:mo>
<mml:mo>&#x2217;</mml:mo>
<mml:mo stretchy="true">(</mml:mo>
<mml:mfrac>
<mml:mn>1.31</mml:mn>
<mml:mi>HDL</mml:mi>
</mml:mfrac>
<mml:mo stretchy="true">)</mml:mo>
</mml:math>
</disp-formula>
<disp-formula id="E4">
<mml:math id="M4">
<mml:mtext>Females</mml:mtext>
<mml:mo>:</mml:mo>
<mml:mi>VAI</mml:mi>
<mml:mo>=</mml:mo>
<mml:mo stretchy="true">(</mml:mo>
<mml:mfrac>
<mml:mi>WC</mml:mi>
<mml:mrow>
<mml:mn>36.58</mml:mn>
<mml:mo>+</mml:mo>
<mml:mn>1.89</mml:mn>
<mml:mo>&#x2217;</mml:mo>
<mml:mi>BMI</mml:mi>
</mml:mrow>
</mml:mfrac>
<mml:mo stretchy="true">)</mml:mo>
<mml:mo>&#x2217;</mml:mo>
<mml:mo stretchy="true">(</mml:mo>
<mml:mfrac>
<mml:mi>TG</mml:mi>
<mml:mn>0.81</mml:mn>
</mml:mfrac>
<mml:mo stretchy="true">)</mml:mo>
<mml:mo>&#x2217;</mml:mo>
<mml:mo stretchy="true">(</mml:mo>
<mml:mfrac>
<mml:mn>1.52</mml:mn>
<mml:mi>HDL</mml:mi>
</mml:mfrac>
<mml:mo stretchy="true">)</mml:mo>
</mml:math>
</disp-formula>
</sec>
<sec id="sec9">
<title>Definition of OAB</title>
<p>Overactive bladder (OAB) is a condition primarily characterized by urinary frequency, urgency urinary incontinence (UUI), and nocturia. In this study, standardized questionnaires were administered during face-to-face interviews conducted by trained personnel to collect the necessary data. The severity of UUI was determined by two questions: &#x201C;In the past 12&#x202F;months, have you experienced urine leakage or loss of bladder control due to urinary urgency or pressure, and been unable to reach the toilet in time?&#x201D; and &#x201C;How frequently does this occur?&#x201D; Nocturia was assessed on the basis of the following question: &#x201C;In the past 30&#x202F;days, how many times did you typically wake up at night to urinate, from the time you went to bed until you got up in the morning?&#x201D; Ultimately, the severity of OAB for each participant was assessed using the Overactive Bladder Symptom Score (OABSS), where a total score of three or higher was deemed indicative of the presence of OAB (<xref ref-type="bibr" rid="ref17">17</xref>).</p>
</sec>
<sec id="sec10">
<title>Definition of covariates</title>
<p>Drawing from the existing literature, the following variables were identified as covariates: gender, age, ethnicity, educational attainment, marital situation, income-to-poverty ratio, smoking habits, alcohol intake, and the occurrence of hypertension or diabetes. Ethnicity was grouped into non-Hispanic White, non-Hispanic Black, Mexican American, other Hispanic, and other racial categories. Marital situation was categorized as either living alone or being married/in a cohabiting relationship. The educational level is classified into three categories: below high school, high school, or above high school. The poverty-to-income ratios (PIRs) were categorized as &#x003C;1.5, 1.5&#x2013;3.5, and &#x003E;3.5. Smoking and alcohol consumption were determined on the basis of the following questions: &#x201C;Have you ever smoked at least 100 cigarettes in your lifetime?&#x201D; and &#x201C;Do you consume at least 12 alcoholic beverages per year?&#x201D; (<xref ref-type="bibr" rid="ref18">18</xref>).</p>
</sec>
<sec id="sec11">
<title>Statistical analysis</title>
<p>In this study, the NHANES-recommended sample weights were utilized for analysis. Continuous variables were presented as the mean, accompanied by their standard deviations, whereas categorical variables were denoted as percentages. The LAP and VAI data were stratified into quartiles, with the lowest quartile serving as the baseline comparison group. To explore the associations between LAP, VAI, and OAB, multivariable logistic regression models were employed to estimate odds ratios (ORs) and their corresponding 95% confidence intervals (CIs) for each variable. Model 1 served as the unadjusted baseline, without considering any confounding variables. Model 2 incorporated adjustments for sex, age, race, educational level, marital status, and poverty-income ratio (PIR). Model 3 extended these adjustments by further accounting for smoking history, alcohol use, hypertension, and diabetes, in addition to the variables included in Model 2. Subgroup analyses were carried out based on sex, age, race, educational attainment, smoking history, alcohol intake, and diabetes status. All statistical assessments were executed using EmpowerStats version 4.2 software, with all tests conducted on a two-tailed basis. Statistical significance was established at a <italic>p-</italic>value &#x003C;0.05.</p>
</sec>
</sec>
<sec sec-type="results" id="sec12">
<title>Results</title>
<sec id="sec13">
<title>Baseline characteristics of participants</title>
<p><xref ref-type="table" rid="tab1">Table 1</xref> summarizes the baseline characteristics of the participants. On the basis of the data analysis of 28,704 participants who met the inclusion and exclusion criteria, 5,776 (20.12%) were diagnosed with overactive bladder syndrome (OAB), and 22,958 (79.88%) did not have OAB. Among these participants, 62.88% were women, with a mean age of 47.21&#x202F;years. Compared with participants without OAB, those with OAB were more likely to be female, older, have a larger waist circumference, live alone, have a lower educational level, be diagnosed with diabetes, and have higher LAP and VAI values (all <italic>p</italic>&#x202F;&#x003C;&#x202F;0.05).</p>
<table-wrap position="float" id="tab1">
<label>Table 1</label>
<caption>
<p>Baseline characteristics of participants in the NHANES 2005&#x2013;2018.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th>Characteristics</th>
<th align="left" valign="top">Total (<italic>N</italic> =&#x202F;28,704)</th>
<th align="left" valign="top">Non-OAB (<italic>N</italic> =&#x202F;22,928)</th>
<th align="left" valign="top">OAB (<italic>N</italic> =&#x202F;5,776)</th>
<th align="left" valign="top"><italic>p</italic>-value</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="top">Age (mean&#x202F;&#x00B1;&#x202F;SE)</td>
<td align="left" valign="top">47.21 (46.74, 47.68)</td>
<td align="left" valign="top">45.41 (44.95, 45.87)</td>
<td align="left" valign="top">57.09 (56.44, 57.75)</td>
<td align="left" valign="top">&#x003C;0.001</td>
</tr>
<tr>
<td align="left" valign="top">Waist circumference (mean&#x202F;&#x00B1;&#x202F;SE)</td>
<td align="left" valign="top">99.42 (99.01, 99.83)</td>
<td align="left" valign="top">98.43 (97.99, 98.87)</td>
<td align="left" valign="top">104.86 (104.24, 105.47)</td>
<td align="left" valign="top">&#x003C;0.001</td>
</tr>
<tr>
<td align="left" valign="top" colspan="4">Sex, <italic>n</italic> (%)</td>
<td align="left" valign="top">&#x003C;0.0001</td>
</tr>
<tr>
<td align="left" valign="top">&#x2003;Male</td>
<td align="left" valign="top">14,243 (49.01%)</td>
<td align="left" valign="top">11,896 (51.15%)</td>
<td align="left" valign="top">2,347 (37.32%)</td>
<td/>
</tr>
<tr>
<td align="left" valign="top">&#x2003;Female</td>
<td align="left" valign="top">14,461 (50.99%)</td>
<td align="left" valign="top">11,032 (48.85%)</td>
<td align="left" valign="top">3,429 (62.68%)</td>
<td/>
</tr>
<tr>
<td align="left" valign="top" colspan="4">Race, <italic>n</italic> (%)</td>
<td align="left" valign="top">&#x003C;0.0001</td>
</tr>
<tr>
<td align="left" valign="top">&#x2003;Mexican American</td>
<td align="left" valign="top">4,447 (8.05%)</td>
<td align="left" valign="top">3,583 (8.15%)</td>
<td align="left" valign="top">864 (7.49%)</td>
<td/>
</tr>
<tr>
<td align="left" valign="top">&#x2003;Other Hispanic</td>
<td align="left" valign="top">2,618 (5.07%)</td>
<td align="left" valign="top">2,059 (5.00%)</td>
<td align="left" valign="top">559 (5.40%)</td>
<td/>
</tr>
<tr>
<td align="left" valign="top">&#x2003;Non-Hispanic White</td>
<td align="left" valign="top">12,922 (69.80%)</td>
<td align="left" valign="top">10,509 (70.50%)</td>
<td align="left" valign="top">2,413 (65.96%)</td>
<td/>
</tr>
<tr>
<td align="left" valign="top">&#x2003;Non-Hispanic Black</td>
<td align="left" valign="top">5,843 (10.20%)</td>
<td align="left" valign="top">4,260 (9.12%)</td>
<td align="left" valign="top">1,583 (16.12%)</td>
<td/>
</tr>
<tr>
<td align="left" valign="top">&#x2003;Other race&#x2014;including multi-racial</td>
<td align="left" valign="top">2,874 (6.88%)</td>
<td align="left" valign="top">2,517 (7.22%)</td>
<td align="left" valign="top">357 (5.03%)</td>
<td/>
</tr>
<tr>
<td align="left" valign="top" colspan="4">Education, <italic>n</italic> (%)</td>
<td align="left" valign="top">&#x003C;0.0001</td>
</tr>
<tr>
<td align="left" valign="top">&#x2003;Less than high school</td>
<td align="left" valign="top">6,683 (14.82%)</td>
<td align="left" valign="top">4,746 (13.14%)</td>
<td align="left" valign="top">1,937 (23.98%)</td>
<td/>
</tr>
<tr>
<td align="left" valign="top">&#x2003;High school</td>
<td align="left" valign="top">6,630 (23.09%)</td>
<td align="left" valign="top">5,243 (22.66%)</td>
<td align="left" valign="top">1,387 (25.48%)</td>
<td/>
</tr>
<tr>
<td align="left" valign="top">&#x2003;More than high school</td>
<td align="left" valign="top">15,391 (62.09%)</td>
<td align="left" valign="top">12,939 (64.20%)</td>
<td align="left" valign="top">2,452 (50.54%)</td>
<td/>
</tr>
<tr>
<td align="left" valign="top" colspan="4">Marital status, <italic>n</italic> (%)</td>
<td align="left" valign="top">&#x003C;0.0001</td>
</tr>
<tr>
<td align="left" valign="top">&#x2003;Living alone</td>
<td align="left" valign="top">11,346 (35.41%)</td>
<td align="left" valign="top">8,698 (34.56%)</td>
<td align="left" valign="top">2,648 (40.06%)</td>
<td/>
</tr>
<tr>
<td align="left" valign="top">&#x2003;Married/Living with a partner</td>
<td align="left" valign="top">17,358 (64.59%)</td>
<td align="left" valign="top">14,230 (65.44%)</td>
<td align="left" valign="top">3,128 (59.94%)</td>
<td/>
</tr>
<tr>
<td align="left" valign="top" colspan="4">Poverty-income ratio, <italic>n</italic> (%)</td>
<td align="left" valign="top">&#x003C;0.0001</td>
</tr>
<tr>
<td align="left" valign="top">&#x2003;&#x003C;1.5</td>
<td align="left" valign="top">10,279 (24.11%)</td>
<td align="left" valign="top">7,710 (22.45%)</td>
<td align="left" valign="top">2,569 (33.23%)</td>
<td/>
</tr>
<tr>
<td align="left" valign="top">&#x2003;1.5&#x2013;3.5</td>
<td align="left" valign="top">9,447 (31.98%)</td>
<td align="left" valign="top">7,475 (31.32%)</td>
<td align="left" valign="top">1,972 (35.59%)</td>
<td/>
</tr>
<tr>
<td align="left" valign="top">&#x2003;&#x003E;3.5</td>
<td align="left" valign="top">8,978 (43.91%)</td>
<td align="left" valign="top">7,743 (46.24%)</td>
<td align="left" valign="top">1,235 (31.18%)</td>
<td/>
</tr>
<tr>
<td align="left" valign="top" colspan="4">Smoking status, <italic>n</italic> (%)</td>
<td align="left" valign="top">&#x003C;0.0001</td>
</tr>
<tr>
<td align="left" valign="top">&#x2003;No</td>
<td align="left" valign="top">15,552 (54.28%)</td>
<td align="left" valign="top">12,775 (55.51%)</td>
<td align="left" valign="top">2,777 (47.56%)</td>
<td/>
</tr>
<tr>
<td align="left" valign="top">&#x2003;Yes</td>
<td align="left" valign="top">13,152 (45.72%)</td>
<td align="left" valign="top">10,153 (44.49%)</td>
<td align="left" valign="top">2,999 (52.44%)</td>
<td/>
</tr>
<tr>
<td align="left" valign="top" colspan="4">Alcohol intake, <italic>n</italic> (%)</td>
<td align="left" valign="top">&#x003C;0.0001</td>
</tr>
<tr>
<td align="left" valign="top">&#x2003;No</td>
<td align="left" valign="top">8,829 (25.46%)</td>
<td align="left" valign="top">6,607 (23.84%)</td>
<td align="left" valign="top">2,222 (34.30%)</td>
<td/>
</tr>
<tr>
<td align="left" valign="top">&#x2003;Yes</td>
<td align="left" valign="top">19,875 (74.54%)</td>
<td align="left" valign="top">16,321 (76.16%)</td>
<td align="left" valign="top">3,554 (65.70%)</td>
<td/>
</tr>
<tr>
<td align="left" valign="top" colspan="4">Diabetes, <italic>n</italic> (%)</td>
<td align="left" valign="top">&#x003C;0.0001</td>
</tr>
<tr>
<td align="left" valign="top">&#x2003;No</td>
<td align="left" valign="top">24,473 (88.71%)</td>
<td align="left" valign="top">20,293 (90.95%)</td>
<td align="left" valign="top">4,180 (76.47%)</td>
<td/>
</tr>
<tr>
<td align="left" valign="top">&#x2003;Yes</td>
<td align="left" valign="top">3,574 (9.19%)</td>
<td align="left" valign="top">2,175 (7.19%)</td>
<td align="left" valign="top">1,399 (20.17%)</td>
<td/>
</tr>
<tr>
<td align="left" valign="top">&#x2003;Borderline</td>
<td align="left" valign="top">657 (2.09%)</td>
<td align="left" valign="top">460 (1.86%)</td>
<td align="left" valign="top">197 (3.37%)</td>
<td/>
</tr>
<tr>
<td align="left" valign="top" colspan="4">Hypertension, <italic>n</italic> (%)</td>
<td align="left" valign="top">&#x003C;0.0001</td>
</tr>
<tr>
<td align="left" valign="top">&#x2003;No</td>
<td align="left" valign="top">18,520 (68.40%)</td>
<td align="left" valign="top">15,944 (72.03%)</td>
<td align="left" valign="top">2,576 (48.54%)</td>
<td/>
</tr>
<tr>
<td align="left" valign="top">&#x2003;Yes</td>
<td align="left" valign="top">10,184 (31.60%)</td>
<td align="left" valign="top">6,984 (27.97%)</td>
<td align="left" valign="top">3,200 (51.469%)</td>
<td/>
</tr>
<tr>
<td align="left" valign="top">LAP, median (Q1&#x2013;Q3)</td>
<td align="left" valign="top">50.19 (26.69, 90.99)</td>
<td align="left" valign="top">47.61 (25.31, 87.16)</td>
<td align="left" valign="top">64.67 (36.55, 110.96)</td>
<td align="left" valign="top">&#x003C;0.0001</td>
</tr>
<tr>
<td align="left" valign="top">VAI, median (Q1&#x2013;Q3)</td>
<td align="left" valign="top">1.70 (0.99, 2.98)</td>
<td align="left" valign="top">1.65 (0.97, 2.91)</td>
<td align="left" valign="top">1.96 (1.15, 3.47)</td>
<td align="left" valign="top">&#x003C;0.0001</td>
</tr>
<tr>
<td align="left" valign="top">Age, median (Q1&#x2013;Q3)</td>
<td align="left" valign="top">47.00 (33.00, 60.00)</td>
<td align="left" valign="top">45.00 (32.00, 57.00)</td>
<td align="left" valign="top">59.00 (46.00, 70.00)</td>
<td align="left" valign="top">&#x003C;0.001</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p>LAP, lipid accumulation product; VAI, visceral adiposity index; NHANES, National Health and Nutrition Examination Survey. <sup>&#x002A;</sup><italic>p</italic>&#x202F;&#x003C;&#x202F;0.05.</p>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="sec14">
<title>Associations between LAP, VAI, and OAB</title>
<p>The results of the multivariable linear regression analysis are shown in <xref ref-type="table" rid="tab2">Table 2</xref>. The results indicate a notable link between both LAP and VAI and the likelihood of developing OAB. We analyzed three different models and categorized the LAP and VAI indices into four quartiles. According to the unadjusted model (Model 1), higher LAP and VAI values were associated with an increased incidence of OAB. The odds ratios (ORs) for the highest quartile of LAP (OR&#x202F;=&#x202F;2.407, 95% CI: 2.150, 2.695) and the OR for the highest quartile of VAI (OR&#x202F;=&#x202F;1.726, 95% CI: 1.539, 1.936) were both significantly greater than those for the lowest quartile, with increases of 141 and 72%, respectively. After fully adjusting for all confounding factors (Model 3), the significant associations between LAP, VAI, and OAB persisted. The OR for the highest quartile of LAP (OR&#x202F;=&#x202F;1.555, 95% CI: 1.376, 1.758) was 56% higher than that for the lowest quartile, with a trend <italic>p</italic>-value of &#x003C;0.0001. The OR for the highest quartile of the VAI (OR&#x202F;=&#x202F;1.225, 95% CI: 1.084, 1.384) was 22% higher than that for the lowest quartile, with a trend <italic>p</italic>-value of &#x003C;0.0001.</p>
<table-wrap position="float" id="tab2">
<label>Table 2</label>
<caption>
<p>Multivariate logistic regression analysis of LAP and VAI with overactive bladder.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="top" rowspan="2">OAB</th>
<th align="center" valign="top" colspan="3">OR (95% CI), <italic>p</italic>-value</th>
</tr>
<tr>
<th align="left" valign="top">Model 1</th>
<th align="left" valign="top">Model 2</th>
<th align="left" valign="top">Model 3</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="middle" colspan="4">LAP</td>
</tr>
<tr>
<td align="left" valign="middle">Continuous</td>
<td align="left" valign="middle">1.003 (1.002, 1.003)&#x202F;&#x003C;&#x202F;0.0001</td>
<td align="left" valign="middle">1.003 (1.002, 1.003)&#x202F;&#x003C;&#x202F;0.0001</td>
<td align="left" valign="middle">1.002 (1.001, 1.002)&#x202F;&#x003C;&#x202F;0.0001</td>
</tr>
<tr>
<td align="left" valign="middle" colspan="4">Categories</td>
</tr>
<tr>
<td align="left" valign="middle">&#x2003;Q1</td>
<td align="left" valign="middle">Reference</td>
<td align="left" valign="middle">Reference</td>
<td align="left" valign="middle">Reference</td>
</tr>
<tr>
<td align="left" valign="middle">&#x2003;Q2</td>
<td align="left" valign="middle">1.530 (1.347, 1.737)&#x202F;&#x003C;&#x202F;0.0001</td>
<td align="left" valign="middle">1.182 (1.043, 1.340) 0.0101</td>
<td align="left" valign="middle">1.127 (0.996, 1.276) 0.0607</td>
</tr>
<tr>
<td align="left" valign="middle">&#x2003;Q3</td>
<td align="left" valign="middle">2.070 (1.827, 2.346)&#x202F;&#x003C;&#x202F;0.0001</td>
<td align="left" valign="middle">1.485 (1.305, 1.691)&#x202F;&#x003C;&#x202F;0.0001</td>
<td align="left" valign="middle">1.350 (1.184, 1.538)&#x202F;&#x003C;&#x202F;0.0001</td>
</tr>
<tr>
<td align="left" valign="middle">&#x2003;Q4</td>
<td align="left" valign="middle">2.407 (2.150, 2.695)&#x202F;&#x003C;&#x202F;0.0001</td>
<td align="left" valign="middle">1.878 (1.660, 2.125)&#x202F;&#x003C;&#x202F;0.0001</td>
<td align="left" valign="middle">1.555 (1.376, 1.758)&#x202F;&#x003C;&#x202F;0.0001</td>
</tr>
<tr>
<td align="left" valign="middle">&#x2003;<italic>p</italic> for trend</td>
<td align="left" valign="middle">1.327 (1.283, 1.373)&#x202F;&#x003C;&#x202F;0.0001</td>
<td align="left" valign="middle">1.240 (1.192, 1.289)&#x202F;&#x003C;&#x202F;0.0001</td>
<td align="left" valign="middle">1.164 (1.119, 1.210)&#x202F;&#x003C;&#x202F;0.0001</td>
</tr>
<tr>
<td align="left" valign="middle" colspan="4">VAI</td>
</tr>
<tr>
<td align="left" valign="middle">Continuous</td>
<td align="left" valign="middle">1.040 (1.028, 1.052)&#x202F;&#x003C;&#x202F;0.0001</td>
<td align="left" valign="middle">1.036 (1.023, 1.048)&#x202F;&#x003C;&#x202F;0.0001</td>
<td align="left" valign="middle">1.020 (1.009, 1.031) 0.0007</td>
</tr>
<tr>
<td align="left" valign="middle" colspan="4">Categories</td>
</tr>
<tr>
<td align="left" valign="middle">&#x2003;Q1</td>
<td align="left" valign="middle">Reference</td>
<td align="left" valign="middle">Reference</td>
<td align="left" valign="middle">Reference</td>
</tr>
<tr>
<td align="left" valign="middle">&#x2003;Q2</td>
<td align="left" valign="middle">1.216 (1.070, 1.382) 0.0034</td>
<td align="left" valign="middle">1.080 (0.944, 1.234) 0.2646</td>
<td align="left" valign="middle">1.035 (0.905, 1.183) 0.6180</td>
</tr>
<tr>
<td align="left" valign="middle">&#x2003;Q3</td>
<td align="left" valign="middle">1.453 (1.269, 1.665)&#x202F;&#x003C;&#x202F;0.0001</td>
<td align="left" valign="middle">1.214 (1.048, 1.405) 0.0110</td>
<td align="left" valign="middle">1.105 (0.957, 1.275) 0.1758</td>
</tr>
<tr>
<td align="left" valign="middle">&#x2003;Q4</td>
<td align="left" valign="middle">1.726 (1.539, 1.936)&#x202F;&#x003C;&#x202F;0.0001</td>
<td align="left" valign="middle">1.449 (1.279, 1.642)&#x202F;&#x003C;&#x202F;0.0001</td>
<td align="left" valign="middle">1.225 (1.084, 1.384) 0.0016</td>
</tr>
<tr>
<td align="left" valign="middle">&#x2003;<italic>p</italic> for trend</td>
<td align="left" valign="middle">1.199 (1.157, 1.241)&#x202F;&#x003C;&#x202F;0.0001</td>
<td align="left" valign="middle">1.134 (1.088, 1.181)&#x202F;&#x003C;&#x202F;0.0001</td>
<td align="left" valign="middle">1.071 (1.030, 1.115) 0.0010</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p>OAB, overactive bladder; VAI, visceral adiposity index; LAP, lipid accumulation product; NHANES, National Health and Nutrition Examination Survey; OR, odds ratio; CI, confidence interval.</p>
</table-wrap-foot>
</table-wrap>
<p>To further visualize the relationships among the LAP, VAI, and OAB, we performed smooth curve fitting with Model 3. <xref ref-type="fig" rid="fig2">Figure 2</xref> illustrates the nonlinear associations among the LAP, VAI, and OAB. A threshold effect analysis was subsequently conducted to clarify the associations (<xref ref-type="table" rid="tab3">Table 3</xref>). The turning point for LAP was identified at 86.234, with a likelihood ratio &#x003C;0.001, indicating that when LAP levels drop below 86.23, each unit increase in LAP is associated with a 0.6% increase in OAB risk. When LAP levels exceeded 86.234, the correlation between LAP and OAB risk diminished, suggesting that further increases in LAP did not lead to a statistically significant increase in OAB risk. The results for the VAI exhibited a similar pattern, with a turning point at 1.49 (likelihood ratio 0.025), suggesting that the VAI had different effects on OAB risk below and above this threshold.</p>
<fig position="float" id="fig2">
<label>Figure 2</label>
<caption>
<p>Nonlinear relationships between LAP <bold>(A)</bold> VAI <bold>(B)</bold>, and OAB. The solid red line represents the smooth curve fit between variables. Blue bands represent the 95% confidence interval from the fit.</p>
</caption>
<graphic xlink:href="fmed-12-1601863-g002.tif" mimetype="image" mime-subtype="tiff">
<alt-text content-type="machine-generated">Two graphs show relationships with OAB. Graph A shows LAP on the x-axis, and Graph B shows VAI on the x-axis. Both graphs include a red line indicating trends and blue dotted lines for confidence intervals. The y-axis for both is labeled OAB, ranging from 0.15 to 0.30.</alt-text>
</graphic>
</fig>
<table-wrap position="float" id="tab3">
<label>Table 3</label>
<caption>
<p>Threshold effect analysis of LAP and VAI on OAB in the NHANES 2005&#x2013;2018.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="top">Threshold effect analysis</th>
<th align="center" valign="top">OAB OR (95% CI) <italic>p</italic>-value</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="middle" colspan="2">LAP</td>
</tr>
<tr>
<td align="left" valign="middle">Inflection point of LAP (K)</td>
<td align="center" valign="middle">86.23</td>
</tr>
<tr>
<td align="left" valign="middle">&#x003C;K slope</td>
<td align="center" valign="middle">1.01 (1.00, 1.01)&#x202F;&#x003C;&#x202F;0.0001</td>
</tr>
<tr>
<td align="left" valign="middle">&#x003E;K slope</td>
<td align="center" valign="middle">1.00 (1.00, 1.00) 0.0164</td>
</tr>
<tr>
<td align="left" valign="middle">Log-likelihood ratio test</td>
<td align="center" valign="middle">&#x003C;0.001</td>
</tr>
<tr>
<td align="left" valign="middle" colspan="2">VAI</td>
</tr>
<tr>
<td align="left" valign="middle">Inflection point of VAI (K)</td>
<td align="center" valign="middle">1.49</td>
</tr>
<tr>
<td align="left" valign="middle">&#x003C;K slope</td>
<td align="center" valign="middle">1.16 (1.04, 1.29) 0.0070</td>
</tr>
<tr>
<td align="left" valign="middle">&#x003E;K slope</td>
<td align="center" valign="middle">1.01 (0.99, 1.04) 0.2220</td>
</tr>
<tr>
<td align="left" valign="middle">Log-likelihood ratio test</td>
<td align="center" valign="middle">0.025</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p>Age, race, sex, level of education, marital status, poverty income ratio, alcohol consumption, smoking status, hypertension status, and diabetes were adjusted.</p>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="sec15">
<title>Subgroup analysis</title>
<p>To evaluate the stability of the associations among the VAI, LAP, and OAB, additional subgroup analyses were performed. Subgroup analyses were stratified by sex, age &#x003C;60&#x202F;years, education level, smoking status, alcohol consumption, and the presence of diabetes. The results of these subgroup analyses, adjusted for all confounding factors, are presented in <xref ref-type="table" rid="tab4">Table 4</xref>. The associations between LAP, VAI, and OAB were consistent across all subgroups.</p>
<table-wrap position="float" id="tab4">
<label>Table 4</label>
<caption>
<p>Subgroup analyses.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="top" rowspan="2">OAB</th>
<th align="center" valign="top" colspan="4">OR (95% CI), <italic>p</italic>-value</th>
</tr>
<tr>
<th align="left" valign="top">LPA</th>
<th align="left" valign="top"><italic>p</italic> interaction</th>
<th align="left" valign="top">VAI</th>
<th align="left" valign="top"><italic>p</italic> interaction</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="middle">Gender</td>
<td/>
<td align="left" valign="middle">0.0012</td>
<td/>
<td align="left" valign="middle">0.0054</td>
</tr>
<tr>
<td align="left" valign="middle">&#x2003;Male</td>
<td align="left" valign="middle">1.064 (0.996, 1.136) 0.0695</td>
<td/>
<td align="left" valign="middle">0.996 (0.934, 1.063) 0.9132</td>
<td/>
</tr>
<tr>
<td align="left" valign="middle">&#x2003;Female</td>
<td align="left" valign="middle">1.238 (1.173, 1.308)&#x202F;&#x003C;&#x202F;0.0001</td>
<td/>
<td align="left" valign="middle">1.131 (1.071, 1.194)&#x202F;&#x003C;&#x202F;0.0001</td>
<td/>
</tr>
<tr>
<td align="left" valign="middle">Age</td>
<td/>
<td align="left" valign="middle">&#x003C;0.0001</td>
<td/>
<td align="left" valign="middle">&#x003C;0.0001</td>
</tr>
<tr>
<td align="left" valign="middle">&#x2003;&#x003C;60</td>
<td align="left" valign="middle">1.297 (1.236, 1.360)&#x202F;&#x003C;&#x202F;0.0001</td>
<td/>
<td align="left" valign="middle">1.176 (1.123, 1.231)&#x202F;&#x003C;&#x202F;0.0001</td>
<td/>
</tr>
<tr>
<td align="left" valign="middle">&#x2003;&#x2265;60</td>
<td align="left" valign="middle">1.023 (0.965, 1.084) 0.4436</td>
<td/>
<td align="left" valign="middle">0.962 (0.903, 1.025) 0.2348</td>
<td/>
</tr>
<tr>
<td align="left" valign="middle">Race</td>
<td/>
<td align="left" valign="middle">0.3204</td>
<td/>
<td align="left" valign="middle">0.5504</td>
</tr>
<tr>
<td align="left" valign="middle">&#x2003;Mexican American</td>
<td align="left" valign="middle">1.232 (1.137, 1.335)&#x202F;&#x003C;&#x202F;0.0001</td>
<td/>
<td align="left" valign="middle">1.064 (0.980, 1.154) 0.1415</td>
<td/>
</tr>
<tr>
<td align="left" valign="middle">&#x2003;Other Hispanic</td>
<td align="left" valign="middle">1.269 (1.133, 1.422) 0.0001</td>
<td/>
<td align="left" valign="middle">1.161 (1.039, 1.298) 0.0102</td>
<td/>
</tr>
<tr>
<td align="left" valign="middle">&#x2003;Non-Hispanic White</td>
<td align="left" valign="middle">1.150 (1.088, 1.215)&#x202F;&#x003C;&#x202F;0.0001</td>
<td/>
<td align="left" valign="middle">1.073 (1.013, 1.136) 0.0179</td>
<td/>
</tr>
<tr>
<td align="left" valign="middle">&#x2003;Non-Hispanic Black</td>
<td align="left" valign="middle">1.191 (1.122, 1.264)&#x202F;&#x003C;&#x202F;0.0001</td>
<td/>
<td align="left" valign="middle">1.046 (0.986, 1.110) 0.1377</td>
<td/>
</tr>
<tr>
<td align="left" valign="middle">&#x2003;Other race&#x2014;including multi-racial</td>
<td align="left" valign="middle">1.096 (0.941, 1.275) 0.2414</td>
<td/>
<td align="left" valign="middle">1.040 (0.916, 1.181) 0.5450</td>
<td/>
</tr>
<tr>
<td align="left" valign="middle">Education</td>
<td/>
<td align="left" valign="middle">0.3444</td>
<td/>
<td align="left" valign="middle">0.8568</td>
</tr>
<tr>
<td align="left" valign="middle">&#x2003;Less than high school</td>
<td align="left" valign="middle">1.196 (1.109, 1.291)&#x202F;&#x003C;&#x202F;0.0001</td>
<td/>
<td align="left" valign="middle">1.075 (0.999, 1.156) 0.0550</td>
<td/>
</tr>
<tr>
<td align="left" valign="middle">&#x2003;High school</td>
<td align="left" valign="middle">1.111 (1.030, 1.200) 0.0081</td>
<td/>
<td align="left" valign="middle">1.054 (0.986, 1.128) 0.1260</td>
<td/>
</tr>
<tr>
<td align="left" valign="middle">&#x2003;More than high school</td>
<td align="left" valign="middle">1.177 (1.114, 1.243)&#x202F;&#x003C;&#x202F;0.0001</td>
<td/>
<td align="left" valign="middle">1.078 (1.020, 1.138) 0.0087</td>
<td/>
</tr>
<tr>
<td align="left" valign="middle">Smoke</td>
<td/>
<td align="left" valign="middle">0.1188</td>
<td/>
<td align="left" valign="middle">0.4901</td>
</tr>
<tr>
<td align="left" valign="middle">&#x2003;Yes</td>
<td align="left" valign="middle">1.125 (1.063, 1.191) 0.0001</td>
<td/>
<td align="left" valign="middle">1.056 (0.993, 1.123) 0.0876</td>
<td/>
</tr>
<tr>
<td align="left" valign="middle">&#x2003;No</td>
<td align="left" valign="middle">1.206 (1.136, 1.280)&#x202F;&#x003C;&#x202F;0.0001</td>
<td/>
<td align="left" valign="middle">1.088 (1.031, 1.148) 0.0028</td>
<td/>
</tr>
<tr>
<td align="left" valign="middle">Alcohol use</td>
<td/>
<td align="left" valign="middle">0.8400</td>
<td/>
<td align="left" valign="middle">0.9943</td>
</tr>
<tr>
<td align="left" valign="middle">&#x2003;Yes</td>
<td align="left" valign="middle">1.160 (1.101, 1.222)&#x202F;&#x003C;&#x202F;0.0001</td>
<td/>
<td align="left" valign="middle">1.071 (1.015, 1.131) 0.0143</td>
<td/>
</tr>
<tr>
<td align="left" valign="middle">&#x2003;No</td>
<td align="left" valign="middle">1.172 (1.090, 1.260)&#x202F;&#x003C;&#x202F;0.0001</td>
<td/>
<td align="left" valign="middle">1.071 (1.009, 1.137) 0.0260</td>
<td/>
</tr>
<tr>
<td align="left" valign="middle">Diabetes</td>
<td/>
<td align="left" valign="middle">0.8623</td>
<td/>
<td align="left" valign="middle">0.5698</td>
</tr>
<tr>
<td align="left" valign="middle">&#x2003;Yes</td>
<td align="left" valign="middle">1.133 (1.016, 1.264) 0.0273</td>
<td/>
<td align="left" valign="middle">1.113 (1.007, 1.230) 0.0390</td>
<td/>
</tr>
<tr>
<td align="left" valign="middle">&#x2003;No</td>
<td align="left" valign="middle">1.167 (1.120, 1.216)&#x202F;&#x003C;&#x202F;0.0001</td>
<td/>
<td align="left" valign="middle">1.068 (1.022, 1.116) 0.0045</td>
<td/>
</tr>
<tr>
<td align="left" valign="middle">&#x2003;Borderline</td>
<td align="left" valign="middle">1.192 (0.970, 1.465) 0.0980</td>
<td/>
<td align="left" valign="middle">0.984 (0.790, 1.226) 0.8853</td>
<td/>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p>OR, odds ratio; CI, confidence interval.</p>
<p>Age, race, sex, level of education, marital status, poverty income ratio, alcohol consumption, smoking status, hypertension status, and diabetes were adjusted. The strata variable was not included in the model when stratifying by itself.</p>
</table-wrap-foot>
</table-wrap>
<p>It is worth noting that there were notable interactions detected among LAP, VAI, as well as gender and age, with statistical significance at <italic>p</italic>&#x202F;&#x003C;&#x202F;0.05. A statistically significant positive correlation was found in women, but this association was not observed in men, indicating that increased visceral fat accumulation may increase the likelihood of OAB in women. Additionally, significant interactions between LAP, VAI, and age &#x003C;60&#x202F;years were found, whereas the results became nonsignificant in participants aged &#x2265;60&#x202F;years, suggesting that higher levels of LAP and VAI may increase the risk of OAB in individuals aged &#x003C;60&#x202F;years.</p>
</sec>
</sec>
<sec sec-type="discussion" id="sec16">
<title>Discussion</title>
<p>This study evaluated the associations between the lipid accumulation product (LAP), the visceral adiposity index (VAI), and overactive bladder (OAB) through a cross-sectional analysis of 28,704 adults. The results of multivariate logistic regression analysis revealed a significant positive correlation between the levels of LAP and VAI and the incidence of OAB. Additionally, a non-linear relationship was observed between LAP, VAI, and OAB, indicating that within certain value ranges, both LAP and VAI could be associated with a reduced risk of OAB. Consequently, there is a basis for considering the predictive value of LAP and VAI in the onset of OAB.</p>
<p>The relationship between OAB and obesity is complex and interdependent (<xref ref-type="bibr" rid="ref41">41</xref>). Numerous studies have established a connection between obesity and the development of OAB. For instance, a meta-analysis found that women with a body fat percentage above 32% have a 95% increased risk of developing OAB compared to those with a body fat percentage below this threshold (<xref ref-type="bibr" rid="ref41">41</xref>). Further research indicates that an increase in LAP is linked to an elevated risk of stress urinary incontinence (<xref ref-type="bibr" rid="ref20">20</xref>). Additionally, the accumulation of abdominal fat, particularly in the context of obesity, is a significant risk factor for both the onset and progression of OAB (<xref ref-type="bibr" rid="ref21">21</xref>). Increased abdominal pressure associated with obesity can compress the bladder, reducing its capacity and ability to store urine. This compression may impair bladder function and contribute to the development of OAB (<xref ref-type="bibr" rid="ref22">22</xref>). Obesity is also linked to a chronic state of low-grade systemic inflammation. Increased visceral fat tissue releases various pro-inflammatory cytokines, which can disrupt the neuromuscular function of the bladder. This disruption may, in turn, raise the risk of developing OAB (<xref ref-type="bibr" rid="ref23">23</xref>). In addition to physical compression and inflammatory factors, obesity is often associated with metabolic syndrome. Conditions such as insulin resistance in the bladder mucosa, hyperglycemia, and hormonal imbalances (including estrogen and leptin) can alter bladder blood flow and neural regulation. These changes may contribute to the onset of OAB (<xref ref-type="bibr" rid="ref24 ref25 ref26">24&#x2013;26</xref>).</p>
<p>Compared to traditional urodynamic evaluations, the LAP and VAI provide simpler, more convenient, and cost-effective methods for diagnosing OAB (<xref ref-type="bibr" rid="ref27">27</xref>, <xref ref-type="bibr" rid="ref28">28</xref>). Research has demonstrated a lack of substantial correlation between either waist circumference (WC) or body mass index (BMI) and OAB symptoms (<xref ref-type="bibr" rid="ref29">29</xref>). Hence, when compared to conventional approaches like BMI and WC, the LAP and VAI exhibit enhanced precision and predictive power (<xref ref-type="bibr" rid="ref30">30</xref>). Recent research indicates that both the LAP and VAI can function as indicators of insulin resistance and metabolic disturbances (<xref ref-type="bibr" rid="ref31 ref32 ref33">31&#x2013;33</xref>). Additionally, studies have demonstrated that LAP is linked to insulin resistance, lipid peroxidation, and systemic inflammatory responses in individuals with type 2 diabetes, all of which constitute risk factors for the development of OAB (<xref ref-type="bibr" rid="ref34">34</xref>). Our research has also established a positive relationship between LAP, VAI, and OAB, hinting at their potential role as diagnostic and preventive benchmarks in clinical practice for OAB. Furthermore, prior studies have suggested that abdominal obesity correlates with a heightened vulnerability to moderate to severe lower urinary tract symptoms among adults (<xref ref-type="bibr" rid="ref35">35</xref>). A study with a cross-sectional design, encompassing 27,309 participants, has uncovered the potential of the VAI to serve as a predictive marker for insulin resistance (<xref ref-type="bibr" rid="ref36">36</xref>). Collectively, these studies establish a groundwork for elucidating the connection between visceral fat accumulation and OAB. Our research utilizes the LAP and VAI, indices indicative of visceral fat accumulation, as diagnostic tools for assessing OAB symptoms and their severity.</p>
<p>Subgroup analyses conducted within this study revealed that elevated levels of LAP and VAI were linked to a heightened risk of OAB among participants younger than 60&#x202F;years and in females. However, this correlation seemed to diminish among individuals aged 60 and above, as well as in males. This observation could potentially be attributed to age-induced alterations in physiological and metabolic processes. In older adults, the presence of comorbidities such as hypertension, diabetes, and cardiovascular disorders may diminish the strength of the relationships between LAP, VAI, and OAB (<xref ref-type="bibr" rid="ref37">37</xref>). Auyeung et al. confirmed that older adults may exhibit some resistance to the effects of overweight and obesity, with even mild obesity or overweight potentially offering some protection (<xref ref-type="bibr" rid="ref38">38</xref>). Moreover, women typically possess a higher fat mass relative to their body weight compared to men, and gender-specific differences exist in the association between obesity and the incidence of OAB (<xref ref-type="bibr" rid="ref39">39</xref>, <xref ref-type="bibr" rid="ref40">40</xref>).</p>
<sec id="sec17">
<title>Study strengths and limitations</title>
<p>Our study boasts several notable strengths. Leveraging the NHANES database from the United States, a cross-sectional approach was employed, benefiting from its highly dependable data owing to stringent quality assurance and standardized methodologies for data acquisition. Furthermore, the utilization of LAP and VAI as indicators of visceral fat distribution offers simplicity, cost-effectiveness, and enhanced precision compared to conventional metrics like WC and BMI, which may be prone to inaccuracies. These indices possess the potential to aid physicians in tailoring more individualized treatment strategies for patients, based on their specific LAP and VAI scores.</p>
<p>Although our study has identified a possible correlation between LAP, VAI, and OAB, it is important to acknowledge several constraints. Primarily, the cross-sectional design of the study prevents the establishment of a definitive causal link between LAP, VAI, and OAB. Moreover, this study only examines their statistical correlation and lacks substantive evidence from clinical research to support such associations. Secondly, the diagnosis of OAB was largely reliant on self-reported questionnaire responses, which could potentially introduce bias stemming from recall inaccuracies. Lastly, and crucially, the study&#x2019;s survey data is predominantly from the U.S. population, necessitating further validation to ascertain the generalizability of these findings to populations in diverse geographical regions.</p>
</sec>
</sec>
<sec sec-type="conclusions" id="sec18">
<title>Conclusion</title>
<p>In summary, using NHANES data, our study has demonstrated a notable correlation between increased LAP and VAI values and the likelihood of developing OAB, suggesting that these indicators could function as valuable predictive biomarkers for OAB. For those with elevated LAP and VAI scores, a holistic approach encompassing dietary adjustments and exercise interventions is advisable to postpone and manage OAB, or specific strategies should be undertaken to forestall and enhance outcomes associated with OAB.</p>
</sec>
</body>
<back>
<sec sec-type="data-availability" id="sec19">
<title>Data availability statement</title>
<p>Publicly available datasets were analyzed in this study. This data can be found here: the datasets that were produced and examined in this research can be accessed on the NHANES website, located at: <ext-link xlink:href="https://www.cdc.gov/nchs/nhanes/index.htm" ext-link-type="uri">https://www.cdc.gov/nchs/nhanes/index.htm</ext-link>.</p>
</sec>
<sec sec-type="ethics-statement" id="sec20">
<title>Ethics statement</title>
<p>The studies involving humans were approved by the NHANES website officially provides access to all data analyzed in this experiment, with all participants having completed the necessary informed consent forms and having undergone the ethical review process, as stipulated by policy. The studies were conducted in accordance with the local legislation and institutional requirements. Written informed consent for participation was not required from the participants or the participants&#x2019; legal guardians/next of kin in accordance with the national legislation and institutional requirements.</p>
</sec>
<sec sec-type="author-contributions" id="sec21">
<title>Author contributions</title>
<p>WW: Investigation, Supervision, Visualization, Software, Funding acquisition, Conceptualization, Validation, Formal analysis, Writing &#x2013; review &#x0026; editing, Resources, Data curation, Methodology, Project administration, Writing &#x2013; original draft. AT: Conceptualization, Validation, Visualization, Software, Writing &#x2013; review &#x0026; editing. ZX: Conceptualization, Validation, Visualization, Software, Writing &#x2013; review &#x0026; editing. XX: Supervision, Funding acquisition, Writing &#x2013; review &#x0026; editing, Visualization, Resources.</p>
</sec>
<sec sec-type="funding-information" id="sec22">
<title>Funding</title>
<p>The author(s) declare that no financial support was received for the research and/or publication of this article.</p>
</sec>
<ack>
<p>We acknowledge with gratitude the contributions made by the participants and survey staff of the National Health and Nutrition Examination Survey (NHANES).</p>
</ack>
<sec sec-type="COI-statement" id="sec23">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec sec-type="ai-statement" id="sec24">
<title>Generative AI statement</title>
<p>The authors declare that no Gen AI was used in the creation of this manuscript.</p>
</sec>
<sec sec-type="disclaimer" id="sec25">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="ref1"><label>1.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Peyronnet</surname> <given-names>B</given-names></name> <name><surname>Mironska</surname> <given-names>E</given-names></name> <name><surname>Chapple</surname> <given-names>C</given-names></name> <name><surname>Cardozo</surname> <given-names>L</given-names></name> <name><surname>Oelke</surname> <given-names>M</given-names></name> <name><surname>Dmochowski</surname> <given-names>R</given-names></name> <etal/></person-group>. <article-title>A comprehensive review of overactive bladder pathophysiology: on the way to tailored treatment</article-title>. <source>Eur Urol</source>. (<year>2019</year>) <volume>75</volume>:<fpage>988</fpage>&#x2013;<lpage>1000</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.eururo.2019.02.038</pub-id>, PMID: <pub-id pub-id-type="pmid">30922690</pub-id></citation></ref>
<ref id="ref2"><label>2.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wein</surname> <given-names>AJ</given-names></name> <name><surname>Rovner</surname> <given-names>ES</given-names></name></person-group>. <article-title>Definition and epidemiology of overactive bladder</article-title>. <source>Urology</source>. (<year>2002</year>) <volume>60</volume>:<fpage>7</fpage>&#x2013;<lpage>12</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0090-4295(02)01784-3</pub-id>, PMID: <pub-id pub-id-type="pmid">12493342</pub-id></citation></ref>
<ref id="ref3"><label>3.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Eapen</surname> <given-names>RS</given-names></name> <name><surname>Radomski</surname> <given-names>SB</given-names></name></person-group>. <article-title>Review of the epidemiology of overactive bladder</article-title>. <source>Res Rep Urol</source>. (<year>2016</year>) <volume>8</volume>:<fpage>71</fpage>&#x2013;<lpage>6</lpage>. doi: <pub-id pub-id-type="doi">10.2147/RRU.S102441</pub-id>, PMID: <pub-id pub-id-type="pmid">27350947</pub-id></citation></ref>
<ref id="ref4"><label>4.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tubaro</surname> <given-names>A</given-names></name></person-group>. <article-title>Defining overactive bladder: epidemiology and burden of disease</article-title>. <source>Urology</source>. (<year>2004</year>) <volume>64</volume>:<fpage>2</fpage>&#x2013;<lpage>6</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.urology.2004.10.047</pub-id>, PMID: <pub-id pub-id-type="pmid">15621220</pub-id></citation></ref>
<ref id="ref5"><label>5.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Banakhar</surname> <given-names>MA</given-names></name> <name><surname>Al-Shaiji</surname> <given-names>TF</given-names></name> <name><surname>Hassouna</surname> <given-names>MM</given-names></name></person-group>. <article-title>Pathophysiology of overactive bladder</article-title>. <source>Int Urogynecol J</source>. (<year>2012</year>) <volume>23</volume>:<fpage>975</fpage>&#x2013;<lpage>82</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s00192-012-1682-6</pub-id>, PMID: <pub-id pub-id-type="pmid">22310925</pub-id></citation></ref>
<ref id="ref6"><label>6.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hunskaar</surname> <given-names>S</given-names></name></person-group>. <article-title>A systematic review of overweight and obesity as risk factors and targets for clinical intervention for urinary incontinence in women</article-title>. <source>Neurourol Urodyn</source>. (<year>2008</year>) <volume>27</volume>:<fpage>749</fpage>&#x2013;<lpage>57</lpage>. doi: <pub-id pub-id-type="doi">10.1002/nau.20635</pub-id>, PMID: <pub-id pub-id-type="pmid">18951445</pub-id></citation></ref>
<ref id="ref7"><label>7.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ibrahim</surname> <given-names>MM</given-names></name></person-group>. <article-title>Subcutaneous and visceral adipose tissue: structural and functional differences</article-title>. <source>Obes Rev</source>. (<year>2010</year>) <volume>11</volume>:<fpage>11</fpage>&#x2013;<lpage>8</lpage>. doi: <pub-id pub-id-type="doi">10.1111/j.1467-789X.2009.00623.x</pub-id>, PMID: <pub-id pub-id-type="pmid">19656312</pub-id></citation></ref>
<ref id="ref8"><label>8.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Taverna</surname> <given-names>MJ</given-names></name> <name><surname>Mart&#x00ED;nez-Larrad</surname> <given-names>MT</given-names></name> <name><surname>Frechtel</surname> <given-names>GD</given-names></name> <name><surname>Serrano-R&#x00ED;os</surname> <given-names>M</given-names></name></person-group>. <article-title>Lipid accumulation product: a powerful marker of metabolic syndrome in healthy population</article-title>. <source>Eur J Endocrinol</source>. (<year>2011</year>) <volume>164</volume>:<fpage>559</fpage>&#x2013;<lpage>67</lpage>. doi: <pub-id pub-id-type="doi">10.1530/EJE-10-1039</pub-id>, PMID: <pub-id pub-id-type="pmid">21262912</pub-id></citation></ref>
<ref id="ref9"><label>9.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Amato</surname> <given-names>MC</given-names></name> <name><surname>Giordano</surname> <given-names>C</given-names></name></person-group>. <article-title>Visceral adiposity index: an indicator of adipose tissue dysfunction</article-title>. <source>Int J Endocrinol</source>. (<year>2014</year>) <volume>2014</volume>:<fpage>730827</fpage>. doi: <pub-id pub-id-type="doi">10.1155/2014/730827</pub-id>, PMID: <pub-id pub-id-type="pmid">24829577</pub-id></citation></ref>
<ref id="ref10"><label>10.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dai</surname> <given-names>H</given-names></name> <name><surname>Wang</surname> <given-names>W</given-names></name> <name><surname>Chen</surname> <given-names>R</given-names></name> <name><surname>Chen</surname> <given-names>Z</given-names></name> <name><surname>Lu</surname> <given-names>Y</given-names></name> <name><surname>Yuan</surname> <given-names>H</given-names></name></person-group>. <article-title>Lipid accumulation product is a powerful tool to predict non-alcoholic fatty liver disease in Chinese adults</article-title>. <source>Nutr Metab</source>. (<year>2017</year>) <volume>14</volume>:<fpage>49</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12986-017-0206-2</pub-id>, PMID: <pub-id pub-id-type="pmid">28775758</pub-id></citation></ref>
<ref id="ref11"><label>11.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Amato</surname> <given-names>MC</given-names></name> <name><surname>Giordano</surname> <given-names>C</given-names></name> <name><surname>Galia</surname> <given-names>M</given-names></name> <name><surname>Criscimanna</surname> <given-names>A</given-names></name> <name><surname>Vitabile</surname> <given-names>S</given-names></name> <name><surname>Midiri</surname> <given-names>M</given-names></name> <etal/></person-group>. <article-title>Visceral adiposity index: a reliable indicator of visceral fat function associated with cardiometabolic risk</article-title>. <source>Diabetes Care</source>. (<year>2010</year>) <volume>33</volume>:<fpage>920</fpage>&#x2013;<lpage>2</lpage>. doi: <pub-id pub-id-type="doi">10.2337/dc09-1825</pub-id>, PMID: <pub-id pub-id-type="pmid">20067971</pub-id></citation></ref>
<ref id="ref12"><label>12.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kahn</surname> <given-names>HS</given-names></name></person-group>. <article-title>The &#x201C;lipid accumulation product&#x201D; performs better than the body mass index for recognizing cardiovascular risk: a population-based comparison</article-title>. <source>BMC Cardiovasc Disord</source>. (<year>2005</year>) <volume>5</volume>:<fpage>26</fpage>. doi: <pub-id pub-id-type="doi">10.1186/1471-2261-5-26</pub-id>, PMID: <pub-id pub-id-type="pmid">16150143</pub-id></citation></ref>
<ref id="ref13"><label>13.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ahn</surname> <given-names>N</given-names></name> <name><surname>Baumeister</surname> <given-names>SE</given-names></name> <name><surname>Amann</surname> <given-names>U</given-names></name> <name><surname>Rathmann</surname> <given-names>W</given-names></name> <name><surname>Peters</surname> <given-names>A</given-names></name> <name><surname>Huth</surname> <given-names>C</given-names></name> <etal/></person-group>. <article-title>Visceral adiposity index (VAI), lipid accumulation product (LAP), and product of triglycerides and glucose (TyG) to discriminate prediabetes and diabetes</article-title>. <source>Sci Rep</source>. (<year>2019</year>) <volume>9</volume>:<fpage>9693</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41598-019-46187-8</pub-id>, PMID: <pub-id pub-id-type="pmid">31273286</pub-id></citation></ref>
<ref id="ref14"><label>14.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kahn</surname> <given-names>HS</given-names></name></person-group>. <article-title>The lipid accumulation product is better than BMI for identifying diabetes: a population-based comparison</article-title>. <source>Diabetes Care</source>. (<year>2006</year>) <volume>29</volume>:<fpage>151</fpage>&#x2013;<lpage>3</lpage>. doi: <pub-id pub-id-type="doi">10.2337/diacare.29.01.06.dc05-1805</pub-id>, PMID: <pub-id pub-id-type="pmid">16373916</pub-id></citation></ref>
<ref id="ref15"><label>15.</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Johnson</surname> <given-names>CL</given-names></name> <name><surname>Dohrmann</surname> <given-names>SM</given-names></name> <name><surname>Burt</surname> <given-names>VL</given-names></name> <name><surname>Mohadjer</surname> <given-names>LK</given-names></name></person-group>. <source>National health and nutrition examination survey: sample design, 2011&#x2013;2014 (No. 2014)</source>. <publisher-loc>Hyattsville, MD</publisher-loc>: <publisher-name>US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics</publisher-name> (<year>2014</year>).</citation></ref>
<ref id="ref16"><label>16.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname> <given-names>W</given-names></name> <name><surname>Pei</surname> <given-names>Y</given-names></name> <name><surname>Wang</surname> <given-names>J</given-names></name> <name><surname>Liang</surname> <given-names>Q</given-names></name> <name><surname>Chen</surname> <given-names>W</given-names></name></person-group>. <article-title>Association between visceral lipid accumulation indicators and gallstones: a cross-sectional study based on NHANES 2017&#x2013;2020</article-title>. <source>Lipids Health Dis</source>. (<year>2024</year>) <volume>23</volume>:<fpage>345</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12944-024-02319-2</pub-id>, PMID: <pub-id pub-id-type="pmid">39456058</pub-id></citation></ref>
<ref id="ref17"><label>17.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Du</surname> <given-names>YZ</given-names></name> <name><surname>Hu</surname> <given-names>HJ</given-names></name> <name><surname>Yang</surname> <given-names>JQ</given-names></name> <name><surname>Yuan</surname> <given-names>Q</given-names></name> <name><surname>Huang</surname> <given-names>R</given-names></name> <name><surname>Dong</surname> <given-names>QX</given-names></name> <etal/></person-group>. <article-title>The relationship between increased regional body fat and overactive bladder: a population-based study</article-title>. <source>J Health Popul Nutr</source>. (<year>2024</year>) <volume>43</volume>:<fpage>226</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s41043-024-00725-x</pub-id>, PMID: <pub-id pub-id-type="pmid">39719652</pub-id></citation></ref>
<ref id="ref18"><label>18.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname> <given-names>B</given-names></name> <name><surname>Zhao</surname> <given-names>Y</given-names></name> <name><surname>Lin</surname> <given-names>P</given-names></name> <name><surname>Qiu</surname> <given-names>W</given-names></name> <name><surname>Wang</surname> <given-names>S</given-names></name> <name><surname>Gu</surname> <given-names>C</given-names></name> <etal/></person-group>. <article-title>The association between overactive bladder and systemic immunity-inflammation index: a cross-sectional study of NHANES 2005 to 2018</article-title>. <source>Sci Rep</source>. (<year>2024</year>) <volume>14</volume>:<fpage>12579</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41598-024-63448-3</pub-id>, PMID: <pub-id pub-id-type="pmid">38822015</pub-id></citation></ref>
<ref id="ref19"><label>19.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hagovska</surname> <given-names>M</given-names></name> <name><surname>&#x0160;vihra</surname> <given-names>J</given-names></name> <name><surname>Bukov&#x00E1;</surname> <given-names>A</given-names></name> <name><surname>Horbacz</surname> <given-names>A</given-names></name> <name><surname>Dra&#x010D;kov&#x00E1;</surname> <given-names>D</given-names></name> <name><surname>Lupt&#x00E1;k</surname> <given-names>J</given-names></name> <etal/></person-group>. <article-title>The relationship between overweight and overactive bladder symptoms</article-title>. <source>Obes Facts</source>. (<year>2020</year>) <volume>13</volume>:<fpage>297</fpage>&#x2013;<lpage>306</lpage>. doi: <pub-id pub-id-type="doi">10.1159/000506486</pub-id>, PMID: <pub-id pub-id-type="pmid">32396899</pub-id></citation></ref>
<ref id="ref20"><label>20.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>J</given-names></name> <name><surname>Wang</surname> <given-names>D</given-names></name> <name><surname>Tian</surname> <given-names>H</given-names></name> <name><surname>Yang</surname> <given-names>J</given-names></name> <name><surname>Xia</surname> <given-names>H</given-names></name> <name><surname>Guo</surname> <given-names>W</given-names></name></person-group>. <article-title>Association between lipid accumulation products and stress urinary incontinence: a cross-sectional study from NHANES 2005 to 2018</article-title>. <source>Lipids Health Dis</source>. (<year>2024</year>) <volume>23</volume>:<fpage>358</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12944-024-02350-3</pub-id></citation></ref>
<ref id="ref21"><label>21.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Subak</surname> <given-names>LL</given-names></name> <name><surname>Richter</surname> <given-names>HE</given-names></name> <name><surname>Hunskaar</surname> <given-names>S</given-names></name></person-group>. <article-title>Obesity and urinary incontinence: epidemiology and clinical research update</article-title>. <source>J Urol</source>. (<year>2009</year>) <volume>182</volume>:<fpage>S2</fpage>&#x2013;<lpage>7</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.juro.2009.08.071</pub-id>, PMID: <pub-id pub-id-type="pmid">19846133</pub-id></citation></ref>
<ref id="ref22"><label>22.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Osborn</surname> <given-names>DJ</given-names></name> <name><surname>Strain</surname> <given-names>M</given-names></name> <name><surname>Gomelsky</surname> <given-names>A</given-names></name> <name><surname>Rothschild</surname> <given-names>J</given-names></name> <name><surname>Dmochowski</surname> <given-names>R</given-names></name></person-group>. <article-title>Obesity and female stress urinary incontinence</article-title>. <source>Urology</source>. (<year>2013</year>) <volume>82</volume>:<fpage>759</fpage>&#x2013;<lpage>63</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.urology.2013.06.020</pub-id>, PMID: <pub-id pub-id-type="pmid">23972338</pub-id></citation></ref>
<ref id="ref23"><label>23.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pereira</surname> <given-names>SS</given-names></name> <name><surname>Alvarez-Leite</surname> <given-names>JI</given-names></name></person-group>. <article-title>Low-grade inflammation, obesity, and diabetes</article-title>. <source>Curr Obes Rep</source>. (<year>2014</year>) <volume>3</volume>:<fpage>422</fpage>&#x2013;<lpage>31</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s13679-014-0124-9</pub-id>, PMID: <pub-id pub-id-type="pmid">26626919</pub-id></citation></ref>
<ref id="ref24"><label>24.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hsu</surname> <given-names>LN</given-names></name> <name><surname>Hu</surname> <given-names>JC</given-names></name> <name><surname>Chen</surname> <given-names>PY</given-names></name> <name><surname>Lee</surname> <given-names>WC</given-names></name> <name><surname>Chuang</surname> <given-names>YC</given-names></name></person-group>. <article-title>Metabolic syndrome and overactive bladder syndrome may share common pathophysiologies</article-title>. <source>Biomedicine</source>. (<year>2022</year>) <volume>10</volume>:<fpage>1957</fpage>. doi: <pub-id pub-id-type="doi">10.3390/biomedicines10081957</pub-id>, PMID: <pub-id pub-id-type="pmid">36009505</pub-id></citation></ref>
<ref id="ref25"><label>25.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bunn</surname> <given-names>F</given-names></name> <name><surname>Kirby</surname> <given-names>M</given-names></name> <name><surname>Pinkney</surname> <given-names>E</given-names></name> <name><surname>Cardozo</surname> <given-names>L</given-names></name> <name><surname>Chapple</surname> <given-names>C</given-names></name> <name><surname>Chester</surname> <given-names>K</given-names></name> <etal/></person-group>. <article-title>Is there a link between overactive bladder and the metabolic syndrome in women? A systematic review of observational studies</article-title>. <source>Int J Clin Pract</source>. (<year>2015</year>) <volume>69</volume>:<fpage>199</fpage>&#x2013;<lpage>217</lpage>. doi: <pub-id pub-id-type="doi">10.1111/ijcp.12518</pub-id>, PMID: <pub-id pub-id-type="pmid">25495905</pub-id></citation></ref>
<ref id="ref26"><label>26.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Uzun</surname> <given-names>H</given-names></name> <name><surname>Zorba</surname> <given-names>O&#x00DC;</given-names></name></person-group>. <article-title>Metabolic syndrome in female patients with overactive bladder</article-title>. <source>Urology</source>. (<year>2012</year>) <volume>79</volume>:<fpage>72</fpage>&#x2013;<lpage>5</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.urology.2011.08.050</pub-id>, PMID: <pub-id pub-id-type="pmid">22014972</pub-id></citation></ref>
<ref id="ref27"><label>27.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kaneva</surname> <given-names>AM</given-names></name> <name><surname>Bojko</surname> <given-names>ER</given-names></name></person-group>. <article-title>Lipid accumulation product or LAP as an up-to-date clinical biochemical marker of human obesity</article-title>. <source>Health Risk Anal</source>. (<year>2019</year>) <volume>2</volume>:<fpage>164</fpage>&#x2013;<lpage>73</lpage>. doi: <pub-id pub-id-type="doi">10.21668/health.risk/2019.2.18.eng</pub-id></citation></ref>
<ref id="ref28"><label>28.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Blus</surname> <given-names>E</given-names></name> <name><surname>Wojciechowska-Kulik</surname> <given-names>A</given-names></name> <name><surname>Majewska</surname> <given-names>E</given-names></name> <name><surname>Baj</surname> <given-names>Z</given-names></name></person-group>. <article-title>Usefulness of new indicators of obesity (BAI and VAI) in estimation of weight reduction</article-title>. <source>J Am Coll Nutr</source>. (<year>2020</year>) <volume>39</volume>:<fpage>171</fpage>&#x2013;<lpage>7</lpage>. doi: <pub-id pub-id-type="doi">10.1080/07315724.2019.1630024</pub-id>, PMID: <pub-id pub-id-type="pmid">31259669</pub-id></citation></ref>
<ref id="ref29"><label>29.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Elbaset</surname> <given-names>MA</given-names></name> <name><surname>Taha</surname> <given-names>DE</given-names></name> <name><surname>Sharaf</surname> <given-names>DE</given-names></name> <name><surname>Ashour</surname> <given-names>R</given-names></name> <name><surname>El-Hefnawy</surname> <given-names>AS</given-names></name></person-group>. <article-title>Obesity and overactive bladder: is it a matter of body weight, fat distribution or function? A preliminary results</article-title>. <source>Urology</source>. (<year>2020</year>) <volume>143</volume>:<fpage>91</fpage>&#x2013;<lpage>6</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.urology.2020.04.115</pub-id>, PMID: <pub-id pub-id-type="pmid">32473939</pub-id></citation></ref>
<ref id="ref30"><label>30.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>He</surname> <given-names>J</given-names></name> <name><surname>Chen</surname> <given-names>L</given-names></name></person-group>. <article-title>Perspective from NHANES data: synergistic effects of visceral adiposity index and lipid accumulation products on diabetes risk</article-title>. <source>Sci Rep</source>. (<year>2025</year>) <volume>15</volume>:<fpage>258</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41598-024-84034-7</pub-id>, PMID: <pub-id pub-id-type="pmid">39747273</pub-id></citation></ref>
<ref id="ref31"><label>31.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Abruzzese</surname> <given-names>GA</given-names></name> <name><surname>Cerrrone</surname> <given-names>GE</given-names></name> <name><surname>Gamez</surname> <given-names>JM</given-names></name> <name><surname>Graffigna</surname> <given-names>MN</given-names></name> <name><surname>Belli</surname> <given-names>S</given-names></name> <name><surname>Lioy</surname> <given-names>G</given-names></name> <etal/></person-group>. <article-title>Lipid accumulation product (LAP) and visceral adiposity index (VAI) as markers of insulin resistance and metabolic associated disturbances in young argentine women with polycystic ovary syndrome</article-title>. <source>Horm Metab Res</source>. (<year>2017</year>) <volume>49</volume>:<fpage>23</fpage>&#x2013;<lpage>9</lpage>. doi: <pub-id pub-id-type="doi">10.1055/s-0042-113463</pub-id></citation></ref>
<ref id="ref32"><label>32.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pineda</surname> <given-names>H</given-names></name> <name><surname>Castro</surname> <given-names>J</given-names></name> <name><surname>Lares</surname> <given-names>M</given-names></name> <name><surname>Hu&#x00E9;rfano</surname> <given-names>T</given-names></name> <name><surname>Brito</surname> <given-names>S</given-names></name> <name><surname>Velasco</surname> <given-names>M</given-names></name></person-group>. <article-title>Lipid accumulation product (LAP) and visceral adiposity index (VAI) a simple and clinically useful surrogate marker for metabolic syndrome and cardiovascular disease predictor in non-diabetic Venezuelan adults</article-title>. <source>J Pharm Pharm Sci</source>. (<year>2017</year>) <volume>2</volume>:<fpage>1</fpage>&#x2013;<lpage>8</lpage>. doi: <pub-id pub-id-type="doi">10.24218/vjpps.2017.20</pub-id></citation></ref>
<ref id="ref33"><label>33.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Xia</surname> <given-names>C</given-names></name> <name><surname>Li</surname> <given-names>R</given-names></name> <name><surname>Zhang</surname> <given-names>S</given-names></name> <name><surname>Gong</surname> <given-names>L</given-names></name> <name><surname>Ren</surname> <given-names>W</given-names></name> <name><surname>Wang</surname> <given-names>Z</given-names></name> <etal/></person-group>. <article-title>Lipid accumulation product is a powerful index for recognizing insulin resistance in non-diabetic individuals</article-title>. <source>Eur J Clin Nutr</source>. (<year>2012</year>) <volume>66</volume>:<fpage>1035</fpage>&#x2013;<lpage>8</lpage>. doi: <pub-id pub-id-type="doi">10.1038/ejcn.2012.83</pub-id></citation></ref>
<ref id="ref34"><label>34.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mirmiran</surname> <given-names>P</given-names></name> <name><surname>Bahadoran</surname> <given-names>Z</given-names></name> <name><surname>Azizi</surname> <given-names>F</given-names></name></person-group>. <article-title>Lipid accumulation product is associated with insulin resistance, lipid peroxidation, and systemic inflammation in type 2 diabetic patients</article-title>. <source>Endocrinol Metab</source>. (<year>2014</year>) <volume>29</volume>:<fpage>443</fpage>&#x2013;<lpage>9</lpage>. doi: <pub-id pub-id-type="doi">10.3803/EnM.2014.29.4.443</pub-id>, PMID: <pub-id pub-id-type="pmid">25325262</pub-id></citation></ref>
<ref id="ref35"><label>35.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Laven</surname> <given-names>BA</given-names></name> <name><surname>Orsini</surname> <given-names>N</given-names></name> <name><surname>Andersson</surname> <given-names>SO</given-names></name> <name><surname>Johansson</surname> <given-names>JE</given-names></name> <name><surname>Gerber</surname> <given-names>GS</given-names></name> <name><surname>Wolk</surname> <given-names>A</given-names></name></person-group>. <article-title>Birth weight, abdominal obesity and the risk of lower urinary tract symptoms in a population based study of Swedish men</article-title>. <source>J Urol</source>. (<year>2008</year>) <volume>179</volume>:<fpage>1891</fpage>&#x2013;<lpage>6</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.juro.2008.01.029</pub-id>, PMID: <pub-id pub-id-type="pmid">18353377</pub-id></citation></ref>
<ref id="ref36"><label>36.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname> <given-names>K</given-names></name> <name><surname>Luan</surname> <given-names>H</given-names></name> <name><surname>Pu</surname> <given-names>X</given-names></name> <name><surname>Wang</surname> <given-names>M</given-names></name> <name><surname>Yin</surname> <given-names>J</given-names></name> <name><surname>Gong</surname> <given-names>R</given-names></name></person-group>. <article-title>Association between visceral adiposity index and insulin resistance: a cross-sectional study based on US adults</article-title>. <source>Front Endocrinol</source>. (<year>2022</year>) <volume>13</volume>:<fpage>921067</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fendo.2022.921067</pub-id>, PMID: <pub-id pub-id-type="pmid">35937809</pub-id></citation></ref>
<ref id="ref37"><label>37.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname> <given-names>S</given-names></name> <name><surname>Chai</surname> <given-names>K</given-names></name> <name><surname>Yang</surname> <given-names>J</given-names></name> <name><surname>Wang</surname> <given-names>H</given-names></name></person-group>. <article-title>Association of visceral adiposity index and lipid accumulation product with frailty in US adults: a cross-sectional study from NHANES</article-title>. <source>Lipids Health Dis</source>. (<year>2024</year>) <volume>23</volume>:<fpage>417</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12944-024-02410-8</pub-id>, PMID: <pub-id pub-id-type="pmid">39716265</pub-id></citation></ref>
<ref id="ref38"><label>38.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Auyeung</surname> <given-names>TW</given-names></name> <name><surname>Lee</surname> <given-names>JS</given-names></name> <name><surname>Leung</surname> <given-names>J</given-names></name> <name><surname>Kwok</surname> <given-names>T</given-names></name> <name><surname>Leung</surname> <given-names>PC</given-names></name> <name><surname>Woo</surname> <given-names>J</given-names></name></person-group>. <article-title>Survival in older men may benefit from being slightly overweight and centrally obese&#x2014;a 5-year follow-up study in 4,000 older adults using DXA</article-title>. <source>J Gerontol A</source>. (<year>2010</year>) <volume>65</volume>:<fpage>99</fpage>&#x2013;<lpage>104</lpage>. doi: <pub-id pub-id-type="doi">10.1093/gerona/glp099</pub-id>, PMID: <pub-id pub-id-type="pmid">19628635</pub-id></citation></ref>
<ref id="ref39"><label>39.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname> <given-names>IH</given-names></name> <name><surname>Chun</surname> <given-names>H</given-names></name> <name><surname>Kwon</surname> <given-names>JW</given-names></name></person-group>. <article-title>Gender differences in the effect of obesity on chronic diseases among the elderly Koreans</article-title>. <source>J Korean Med Sci</source>. (<year>2011</year>) <volume>26</volume>:<fpage>250</fpage>&#x2013;<lpage>7</lpage>. doi: <pub-id pub-id-type="doi">10.3346/jkms.2011.26.2.250</pub-id>, PMID: <pub-id pub-id-type="pmid">21286017</pub-id></citation></ref>
<ref id="ref40"><label>40.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Link</surname> <given-names>CL</given-names></name> <name><surname>Steers</surname> <given-names>WD</given-names></name> <name><surname>Kusek</surname> <given-names>JW</given-names></name> <name><surname>McKinlay</surname> <given-names>JB</given-names></name></person-group>. <article-title>The association of adiposity and overactive bladder appears to differ by gender: results from the Boston area community health survey</article-title>. <source>J Urol</source>. (<year>2011</year>) <volume>185</volume>:<fpage>955</fpage>&#x2013;<lpage>63</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.juro.2010.10.048</pub-id>, PMID: <pub-id pub-id-type="pmid">21247604</pub-id></citation></ref>
<ref id="ref41"><label>41.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fry</surname> <given-names>CH</given-names></name></person-group>. <article-title>Obesity and the overactive bladder</article-title>. <source>Curr Bladder Dysfunct Rep</source>. (<year>2013</year>) <volume>8</volume>:<fpage>62</fpage>&#x2013;<lpage>8</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s11884-012-0172-5</pub-id></citation></ref>
</ref-list>
</back>
</article>